Colorectal cancer kills roughly 900,000 people annually, and its treatment landscape has changed little in over a decade. A convergence of synthetic biology and oncology may be about to change that calculus — researchers have built a living therapeutic that can both detect and attack colorectal tumors from inside the gut, using an ordinary probiotic bacterium as the delivery chassis.
The platform centers on a genetically reprogrammed strain of Escherichia coli Nissle 1917 — the same bacterium already used clinically for gut disorders — engineered to respond to ornithine, a metabolite elevated in the tumor microenvironment of both CRC mouse models and human patients in this study's fecal metabolomic analysis. When the bacterium senses ornithine, a bioluminescent reporter activates, enabling non-invasive tumor detection. A second engineered module then releases Dickkopf-3 (DKK3), a naturally occurring antagonist of the Wnt/β-catenin pathway — a signaling cascade that drives proliferation in the majority of colorectal cancers. Oral administration reduced tumor burden and extended survival across several preclinical mouse models. Efficacy was further validated in patient-derived organoids and patient-derived xenograft models, which replicate human tumor biology more faithfully than standard cell lines.
This work is notable for integrating diagnosis and therapy into a single orally deliverable system — a concept called "theranostics" that has been explored mostly with nanoparticles. Using a live bacterium that colonizes the tumor microenvironment, rather than relying on systemic drug distribution, could meaningfully reduce off-target toxicity. E. coli Nissle 1917's established clinical safety profile also shortens the regulatory path compared with entirely novel organisms. That said, the leap from PDX models to human trials remains substantial: gut microbiome variability between individuals could affect colonization efficiency, and immune responses to engineered bacteria in immunocompetent humans are not yet characterized. DKK3's role in Wnt inhibition is well-documented, but its therapeutic window in living tissue will require careful dose calibration. This is an early-stage but genuinely innovative platform — incremental in its use of known components, potentially paradigm-shifting in how they are combined.